Back
ESC Professional Premium Access

Estimated plasma volume in heart failure with reduced ejection fraction: ACE inhibitors versus angiotensin receptor/neprilysin inhibitor in follow up

Session: Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure
Topic: Pharmacotherapy
Speaker: Doctor S. Varga (Sisak, HR)
Event: ESC Congress 2024

Congress Presentation

Add to my library

Like

About the speaker

Doctor Sara Varga

General Hospital Dr. Ivo Pedisic, Sisak (Croatia)
0 follower

7 more presentations in this session

Guideline-directed medical therapy patterns in heart failure with reduced ejection fraction: the OPTIMA-HF registry

Speaker: Doctor S. Paolillo (Naples, IT)

Access
Abstract
Slides
Like
Thumbnail

Quality of life in patients with heart failure and improved ejection fraction: one-year follow-up with ARNI and SGLT2i

Speaker: Professor S. Tadic (Novi Sad, RS)

Access
Abstract
Slides
Like
Thumbnail

Real world evidence of Sacubitril/Valsartan in octogenarian patients with heart failure. Results From the PARACHUTE-HF Study

Speaker: Doctor N. Okuda (Kawagoe, JP)

Access
Abstract
Slides
Like
Thumbnail

Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i

Speaker: Mrs O. Obertynska (Vinnitsa, UA)

Access
Abstract
Slides
Like
Thumbnail

Association of renal circulation at acute phase with decongestion level at discharge in patients admitted for acute decompensated heart failure

Speaker: Doctor K. Kayama (Nagoya, JP)

Access
Abstract
Slides
Like
Thumbnail

Access the full session

Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure

Speakers: Doctor S. Varga, Doctor S. Paolillo, Professor S. Tadic, Doctor N. Okuda, Mrs O. Obertynska...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources